Is Pfizer the Best Dividend Stock in Healthcare?
Pfizer Inc.'s (NYSE: PFE) sales have fallen sharply since its top-selling Lipitor lost patent protection back in 2012. However, steps management has taken to control costs and invest in cancer drugs and biosimilar drug development may position it perfectly for future growth.
In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss Pfizer's strategy and if its stock is a buy.
A full transcript follows the video.
Source: Fool.com
Pfizer Inc. Stock
€23.17
-0.450%
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 29 € there is a positive potential of 25.19% for Pfizer Inc. compared to the current price of 23.17 €.
